First-hand Experience: Practical Insights on the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet
ADVENT On Air
First-hand Experience: Practical Insights on the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet
Dr Linda Stein Gold and Dr Jonathan Silverberg discuss the challenges associated with diagnosis of atopic dermatitis of the hands and feet and how disease severity can be assessed in clinical practice.
ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.
This podcast is intended for healthcare professionals only.
Disclaimer:
This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits
Speaker disclosures:
Dr Jonathan Silverberg: Honoraria as a consultant and/or advisory board member for AbbVie, Alamar, Aldena Therapeutics, Amgen, AOBiome, Apollo Pharma, Arcutis, Arena Pharmaceuticals, Asana, ASLAN Pharmaceuticals, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, FIDE, Galderma, GSK, Incyte, Invea, Kiniksa, LEO Pharma, Lilly, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT Therapeutics, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, Target RWE, Teva, UNION, and UpToDate. Speaker for AbbVie, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi-Genzyme. Institution received grants from Galderma, Incyte, and Pfizer.
Dr Linda Stein Gold: Investigator/advisor and/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi.
© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
MAT-GLB-2402602- 1.0 - 05/2024
MAT-US-2405594 v1.0 - P Exp Date: 06/04/2026
Back to Episodes